Skip to main content
. 2022 Nov 3;2022(11):CD013403. doi: 10.1002/14651858.CD013403.pub2

2. Drugs for the prevention of hereditary angioedema attacks.

Drug Brand Route of administration
Avoralstat Not approved Oral
Berotralstat Orladeyo Oral
C1‐INH(SC) Haegarda SC
C1‐INH‐nf Cinryze Intravenous
pdC1‐INH Berinert Intravenous
rhC1‐INH Ruconest Intravenous
Danazol Danocrine/Cyclomen Oral
Lanadelumab Takhzyro SC
Tranexamic acid Lysteda Oral

C1‐INH: C1 esterase inhibitor; C1‐INH‐nf: nanofiltered C1 esterase inhibitor; C1‐INH(SC): subcutaneous C1 esterase inhibitor; HAE: hereditary angioedema; pdC1‐INH: plasma‐derived C1 esterase inhibitor; rhC1‐INH: recombinant human C1 esterase inhibitor.